The Patent Trial and Appeals Board previously authorized Celgene Corporation to move for sanctions against the Coalition for Affordable Drugs , an entity affiliated with a Kyle Bass hedge fund that had filed several inter partes review petitions against Celgene and other biotech companies. As expected, Celgene's recently filed motion focuses on the Coalition's underlying goal of "profit[ing] by affecting stock prices."